ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 360 filers reported holding ROYALTY PHARMA PLC in Q4 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,302,193 | -44.1% | 238,991 | -35.7% | 0.03% | -42.1% |
Q1 2024 | $11,281,301 | +1799.1% | 371,462 | +1656.5% | 0.06% | +1800.0% |
Q4 2023 | $594,047 | -88.7% | 21,148 | -89.1% | 0.00% | -90.6% |
Q3 2023 | $5,242,797 | +51.4% | 193,176 | +71.5% | 0.03% | +52.4% |
Q2 2023 | $3,462,492 | +187.4% | 112,638 | +236.9% | 0.02% | +200.0% |
Q1 2023 | $1,204,735 | -22.0% | 33,437 | -14.5% | 0.01% | -12.5% |
Q4 2022 | $1,544,955 | -37.8% | 39,093 | -36.8% | 0.01% | -38.5% |
Q3 2022 | $2,485,000 | +1014.3% | 61,852 | +1065.0% | 0.01% | +1200.0% |
Q2 2022 | $223,000 | -85.9% | 5,309 | -86.9% | 0.00% | -83.3% |
Q1 2022 | $1,577,000 | +588.6% | 40,487 | +604.4% | 0.01% | +500.0% |
Q4 2021 | $229,000 | -69.5% | 5,748 | -68.7% | 0.00% | -80.0% |
Q2 2021 | $752,000 | +11.1% | 18,347 | +35.6% | 0.01% | -16.7% |
Q4 2020 | $677,000 | – | 13,535 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
Brown University | 621,759 | $24,224,000 | 5.93% |
Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |